CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. - Wikidata - wikimedia - TriplyDB

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.

http://www.wikidata.org/entity/Q42516415

about

Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients Role of RUNX2 in Breast Carcinogenesis Cyclin D as a therapeutic target in cancer Germline mutations and polymorphisms in the origins of cancers in women.Expression of cell cycle proteins in male breast carcinoma.Systematical detection of significant genes in microarray data by incorporating gene interaction relationship in biological systems.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.Biological effects of ray cartilage extract on human breast cancer cell line MCF-7 and its mechanism.Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma Lack of association between cyclin D1 A870G (rs9344) polymorphism and esophageal squamous cell carcinoma risk: case-control study and meta-analysis Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.An exact algorithm for finding cancer driver somatic genome alterations: the weighted mutually exclusive maximum set cover problem.Immunophenotypic and genomic characterization of papillary carcinomas of the breast.MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.DNA amplifications in breast cancer: genotypic-phenotypic correlations.Phenotype-genotype correlation in familial breast cancer.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.Oncogenes without a Neighboring Tumor-Suppressor Gene Are More Prone to Amplification Functional characterization of EMSY gene amplification in human cancers.Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.Roles of human papillomavirus infection and stathmin in the pathogenesis of sinonasal inverted papilloma.Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors.High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.The role of CCND1 alterations during the progression of cutaneous malignant melanoma.Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization.HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability in human cells.microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis.The effects of alternative splicing on miRNA binding sites in bladder cancer.

P2860

Q26796590-12AD5D77-E47F-4FF0-A47F-AA54FE222C82 Q28084968-B674EAFE-E631-42E1-805B-3B453EB16C94 Q28242623-101D7760-34C0-40D7-9A34-D058EA328D70 Q33606675-46007D86-A11B-4D85-B50B-887EB31D0FAE Q33692284-B6B431F2-C545-47B9-A190-24CD4695D8ED Q33741846-66AEB1F7-AA2E-4E2D-9CEE-E282F13810D0 Q33867326-797F0042-5E6D-4282-87DA-B5864D7DF2BC Q34487091-2FFE1AB1-FCBA-4A50-AA4E-5DB0566F4109 Q35538100-7D6466BB-1DF7-4A17-A6B5-A1B9B6339D52 Q35870797-05A17C3A-3C7A-4FB8-861D-36C0B2A71102 Q36147178-27A9B7AE-5D77-45FC-8206-5EAAF394F7F7 Q36177313-354AEC2C-FBA3-4F16-A7E6-89776E98DF71 Q36182787-E84EFCC9-4C7B-4DAD-B390-903542D56704 Q36200413-C138B49E-3C05-4F98-AEDC-C4972DC05ABA Q36595121-3D37A471-A449-4D76-BE99-93CE6BDDB282 Q36865843-F2590BD1-0A9D-4EB4-81FC-4ADC97089698 Q37130628-C7F258A9-4414-4B1A-9CFE-1809BB48E96B Q37174700-8DC0B401-5B4F-446A-A9CD-C4B4976687F8 Q37763102-DF095318-42B2-44CE-B535-DADB6EACBE34 Q37852615-8C303500-9A36-4CC0-BCD0-80047CA363CE Q37948079-6E96CBB6-E777-4ABD-8B9D-1D6FA5625953 Q38066149-5F7B7E43-68CA-4995-A676-FE96FB0DC8C2 Q38444442-2392FA3F-BC0E-48FC-BFE7-4970421FF1BF Q38675849-C87A3AB6-E573-4775-9F6D-F22AE41EE819 Q38835733-F47B2B43-4140-402D-96A5-A3D56720B395 Q39020973-AEA836A3-4793-47CF-BBD4-FDBCF2F8B514 Q39511351-8E391B99-670A-45F0-ACEE-80CD951F69D9 Q40514940-878B062A-CE99-4169-8F01-E1A670044CD0 Q41454768-715144AA-5AEA-4726-9D62-34007CEC9377 Q41738137-894F2B30-01FB-4643-B7AA-6E444A9E3C55 Q42497397-5285BC02-69FE-4F74-A639-488F93C5F793 Q43715641-1F01C2E1-5F20-45FC-968F-3244FCC3F478 Q43856089-AF4A2777-3846-4814-A1CF-E91487C0CDB1 Q43947658-CD708C93-2EB4-4936-90AF-51A7D7E67EC8 Q44763194-01F0A72D-0DA5-4250-8C0E-5BD45D47486F Q45797188-67AA199E-CAA6-4A44-BCD6-7180433B41E9 Q45992368-F0807417-2764-43FB-BD35-2D07A80AADCA Q47099797-B2097C5D-743E-48E3-B586-7662174BF8B5 Q47142555-D8A70D52-A4E4-4541-9324-6072D0CFBC88 Q47232846-C81FF0B9-FF09-4BC3-9CD2-55F0E16831E2

P2860

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.

http://www.wikidata.org/entity/Q42516415

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@en

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@nl

type

label

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@en

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@nl

prefLabel

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@en

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@nl

P1433

Q42516415-16C5190A-FDE2-4DFB-9137-8BF373B65A91

P1476

Q42516415-CF94F2CF-CC78-4FB7-BC6C-A82BE7E4A31A

P2093

Q42516415-5DB884F5-9370-4579-B4C3-9C79C57FF1B4

Q42516415-B15603D9-2382-468D-975F-590B1B818C53

Q42516415-B544E43C-4644-482E-B43A-1594BD8A2AE9

P2860

Q42516415-0EE464A4-CFB9-42DC-AC37-96EC3DC1818F

Q42516415-8D680CCF-2CA9-4B6E-AB8D-97C66C5952B7

Q42516415-BFE37F31-9241-4E4D-96D2-8E853E53EC56

Q42516415-D6BF0272-5164-4B60-9F40-AA7EE7EA6F9F

P2888

Q42516415-738CDEA9-810D-46DA-B6EE-39E04591C823

P304

Q42516415-6064EFBF-D3F5-4F8C-BEA9-B891FDCA8DCE

P31

Q42516415-7A7B4884-43F1-4F2F-903E-40C7DE9A3E38

P356

Q42516415-B9D7F8EA-1591-41CE-B173-6CAD781D4F86

P407

Q42516415-6109C245-C8B5-45F7-83BD-9723D16DC13A

P433

Q42516415-849FA058-3411-45DA-B312-C33CF5AE76BD

P478

Q42516415-6C2A2048-BE09-40F9-8071-9C287AB805ED

P50

Q42516415-0A8A4604-F58F-4E05-8C7F-C489AEC80AC4

Q42516415-2EF59608-18CF-47A0-86AE-D418504DC407

Q42516415-84EF601D-7D9B-4630-AF5F-B6913298A77B

Q42516415-C5E8A728-E2B2-4E74-8F95-6F1E1905F4CE

Q42516415-FA1BCB5D-F133-4C6C-ADC5-1342FFEF8E31

P577

Q42516415-003521D1-5208-4178-96DE-816E451E9F72

P5875

Q42516415-1EF9E807-5FB0-42F0-BBAE-3BB48FDBBAFB

P6179

Q42516415-C9A99CEC-1681-4E82-B1CE-4903CE8858C1

P698

Q42516415-5F329858-5D0F-4A4A-A716-7528D28B6775

P921

Q42516415-C840E648-6729-4B47-85EA-DEFDA0D8B3AA

P356

S10549-007-9659-8

P1433

Breast Cancer Research and Treatment

P1476

CCND1 amplification and cyclin ...... subgroups and patient outcome.

@en

P2093

Claire E Paish

http://www.w3.org/2001/XMLSchema#string

Maryou B K Lambros

http://www.w3.org/2001/XMLSchema#string

Somaia Elsheikh

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer

Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

P2888

s10549-007-9659-8

P304

325-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-007-9659-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis-Filho

Andrew R. Green

Matthew J. Grainge

Mohammed A Aleskandarany

P577

2007-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6184663

http://www.w3.org/2001/XMLSchema#string

P6179

1050443937

http://www.w3.org/2001/XMLSchema#string

P698

17653856

http://www.w3.org/2001/XMLSchema#string

P921